Session Title : Reimagining Anemia Management in CKD: Evolution with HIF-PHIs
Organized By : Zydus LifeSciences
Session Description:
In India, currently, Desidustat is the only HIF-PHI marketed and available for clinical usage. Since its availability, tens of thousands of Indian patients of CKD and identifying the most suitable patient profiles. Newer evidence also suggests a possible role of this new class of drugs beyond anemia
1. Understand how HIF-PHIs work and why treatment is shifting from ESAs to HIF-PHIs.
2. Review key clinical and real-world evidence for Desidustat and other HIF-PHIs.